BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY

Total Page：16

File Type：pdf, Size：1020Kb

Interdisciplinary Statistics BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY Scott Patterson GlaxoSmithKline Pharmaceuticals Pennsylvania, USA Byron Jones Pfizer Global Research & Development Kent, UK Chapman & Hall/CRC Taylor & Francis Croup Boca Raton London New York Contents Preface xi List of figures xiii List of tables xv 1 Drug Development and Clinical Pharmacology 1 1.1 Aims of This Book 2 1.2 Drug Development 3 1.3 Clinical Pharmacology 5 1.4 Statistics in Clinical Pharmacology 11 1.5 Structure of the Book 14 2 History and Regulation of Bioequivalence 17 2.1 When and How BE Studies Are Performed 19 2.2 Why Are BE Studies Performed? 27 2.3 Deciding When Formulations Are Bioequivalent 28 2.4 Potential Issues with TOST Bioequivalence 32 2.5 Current International Regulation 36 3 Testing for Average Bioequivalence 39 3.1 Background 39 3.2 Linear Model for 2 x 2 Data 44 3.3 Applying the TOST Procedure 49 3.4 Carry-over, Sequence, and Interaction Effects 52 3.5 Checking Assumptions Made about the Linear Model 56 3.6 Power and Sample Size for ABE in the 2x2 Design 58 3.7 Example Where Test and Reference Are Not ABE (il 3.8 Nonparametric Analysis 68 3.9 Some Practical Issues 76 4 BE Studies with More Than Two Periods 79 4.1 Background 80 4.2 Three-period Designs 81 viii CONTENTS 4.3 Within-subject Variability 87 4.4 Robust Analyses for Three Period Designs 90 4.5 Four-period Designs 92 4.6 Designs with More Than Two Treatments 96 4.7 Nonparametric Analyses of Tmax 102 4.8 Technical Appendix: Efficiency 116 4.9 Tables of Data 120 5 Dealing with Unexpected BE Challenges 133 5.1 Restricted Maximum Likelihood Modelling 135 5.2 Failing BE and the DER Assessment 138 5.3 Simulation 143 5.4 Data-based Simulation 145 5.5 Carry-over 147 5.6 Optional Designs 154 5.7 Determining Trial Size 160 5.8 What Outliers Are and How to Handle Their Data 165 5.9 Bayesian BE Assessment 167 5.10 Technical Appendix 170 6 The Future and Recent Past of BE Testing 177 6.1 Brief History 178 6.2 Individual and Population BE 181 6.3 Scaled Average BE 186 7 Clinical Pharmacology Safety Studies 189 7.1 Background 191 7.2 First-time-in-humans 194 7.3 Sub-chronic Dosing Studies 208 7.4 Food-Effect Assessment and DDIs 221 7.5 Dose-Proportionality 233 7.6 Technical Appendix 240 8 QTc 243 8.1 Background 244 8.2 Modelling of QTc Data 247 8.3 Interpreting the QTc Modelling Findings 254 8.4 Design of a Thorough QTc Study in the Future 259 8.5 Technical Appendix 262 9 Clinical Pharmacology Efficacy Studies 269 9.1 Background 270 9.2 Sub-chronic Dosing 274 CONTENTS ix 9.3 Phase Ha and the Proof of Concept 282 9.4 Methodology Studies 294 10 Population Pharmacokinetics 299 10.1 Population and Pharmacokinetics 300 10.2 Absolute and Relative Bioavailability 307 10.3 Age and Gender Pharmacokinetic Studies 311 10.4 Ethnicity 316 10.5 Liver Disease 321 10.6 Kidney Disease 325 10.7 Technical Appendix 328 11 Epilogue 333 Bibliography 335 Index 371.

Copy Link

Recommended publications

CPT Fellowship Psychopharm Focus
Clinical Pharmacology and Toxicology Residency Program, McGill University One year Fellowship in Clinical Pharmacology and Toxicology: Psychopharmacology Focus Fellowship Director: Dr. Theodore Kolivakis, MD, FRCPC Program Director: Dr. Howard Margolese Location: MUHC (70-90%) JGH (10-20%) DH (10-20%) (% Depends on Selectives chosen based on interest of the Fellow) Number of Positions: 1 Length of Program: 1 year. The ‘academic’ year is July 1 to June 30, however ‘off-cycle’ candidates will also be considered Program General Information: The Clinical Pharmacology and Toxicology Fellowship: Psychopharmacology Focus is a one-year supervised training program open to qualified psychiatry residents who have completed their Psychiatry Postgraduate training and are eligible for practice in Canada. This fellowship program is based in the Clinical Psychopharmacology and Therapeutics Unit of the McGill University Health Centre (MUHC), Department of Psychiatry, McGill University, and is carried out in collaboration with a number of University hospitals and centers, namely the Clinical Toxicology Service of the MUHC, Alan Edwards Centre for Research on Pain at the MUHC, Internal Medicine at the MUHC or JGH (Hypertension clinic), Douglas Mental Health University Institute, and the Montreal Neurological Hospital and Institute; as well as the Department of Pharmacy of the MUHC. The objective of this program is to provide advanced training in clinical pharmacology and toxicology with a psychopharmacology focus to residents interested in gaining an expertise in the pharmacological treatment of their patients. Specifically they will learn best practices for 1. patients with complex medication regimes, 2. treatment resistant patients, 3. adverse drug reactions including iatrogenic ADR 4. consultation based care and practices After successfully completing the fellowship it is expected that fellows will become experts in the management of the most difficult psychiatric patients who are often those with significant other medical co-morbidities.
[Show full text]
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
[Show full text]
IJBCP International Journal of Basic & Clinical Pharmacology Antibiotic
Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191567 Original Research Article Antibiotic sensitivity profile and resistance of microorganisms isolated from south Indian population, a hospital based study at Velappanchavady, Chennai, India Brethis C. S.1*, Mahender G.2, Thamizharasan S.1, Suresh Kumar K.3, Sudharson T.3 1Department of Pharmacology, A.C.S Medical College and ABSTRACT Hospital, Velappanchavadi, Chennai, Tamil Nadu, India Background: Increasing rates of antibiotic drug resistance has been noted in 2Department of Forensic recent times and this adversely affects the prognosis and outcomes of patients. Medicine and Toxicology, There is a greater need for local resistance prevalence data in order to guide District Hospital Gajwel, empirical prescription and to identify areas in which medical need for newer Telangana, India antimicrobial agents is greater. 3Department of Forensic Methods: A prospective hospital based observational study was carried out to Medicine and Toxicology, determine antibiotic sensitivity profile and resistance pattern of microorganisms. A.C.S Medical College and Samples were collected from urinary tract infections, while cultures from blood Hospital, Velappanchavadi, stream infections, sputum samples and Serology. Antibiotic susceptibility was Chennai, Tamil Nadu, India determined by the standard disc diffusion method. Data interpretation was based on CLSI, 2017 guidelines for antimicrobial susceptibility testing. Received: 14 April 2019 Results: The predominant isolates from the samples were, Staphylococcus Accepted: 19 April 2019 aureus (16.7%) 67, K. pneumoniae (11.5%) 46, E. coli (29.4%) 118, P. aeruginosa (6%) 24. Escherichia coli, the most common causative organism *Correspondence to: showed high resistance to commonly used drugs such as Ampicillin (60.1%) 71, Dr.
[Show full text]
Clinical Pharmacology and Pharmacogenomics Fellowship Research Training
CCPP COMMITTEE ON CLINICAL PHARMACOLOGY AND PHARMACOGENOMICS Clinical Pharmacology and Pharmacogenomics Fellowship Research Training The Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago, chaired by M. Eileen Dolan, PhD, is seeking motivated trainees for our clinical pharmacology and pharmacogenomics fellowship training program. Candidates should have a PhD, MD, PharmD/PhD or PharmD degree and have successfully completed a clinical residency. Ability to demonstrate a commitment to research, including but not limited to evidence provided by a record of prior publication is encouraged. This program is open to those interested in personalized medicine, pharmacogenomics, new drug development, clinical pharmacology, clinical trial design, genome wide association studies, genetics of drug abuse and/or overcoming drug resistance. Our two-year American Board of Clinical Pharmacology (ABCP) accredited program is a multidisciplinary, comprehensive and collaborative initiative that emphasizes individual creativity in the context of an encouraging environment. The two-year fellowship provides salary support/benefits for protected research time dedicated to research efforts along with support to attend meetings. Trainees will have the opportunity to tailor their work to emphasize clinical, translational or basic science research spending protected time devoted to their research efforts with the remainder dedicated to core curriculum and clinical activities (as applicable). After successful completion, trainees are eligible to become board certified in Clinical Pharmacology. General information at: http://ccpp.uchicago.edu/ or contact the programs’ educational manager, Michelle Domecki at [email protected]. Candidates who are U.S. citizens or permanent residents will be considered for support via an institutional training grant. The University of Chicago is an Equal Opportunity/Affirmative Action Employer.
[Show full text]
Bioavailability and Bioequivalence Studies Submitted in Ndas Or Inds — General Considerations
Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact the CDER Office of Clinical Pharmacology at 301-796-5008 or [email protected]. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2014 Biopharmaceutics Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs— General Considerations Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Avenue, Silver Spring, MD 20993 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm Phone: 301-796-3400; Fax: 301-847-8714 [email protected] U.S. Department of Health and Human Services Food
[Show full text]
Action and Resistance Mechanisms of Antibiotics: a Guide for Clinicians
J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep; 33(3): 300–305. PMCID: PMC5672523 doi: 10.4103/joacp.JOACP_349_15: 10.4103/joacp.JOACP_349_15 PMID: 29109626 Action and resistance mechanisms of antibiotics: A guide for clinicians Garima Kapoor, Saurabh Saigal,1 and Ashok Elongavan2 Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India 1Department of Trauma and Emergency, AIIMS, Bhopal, Madhya Pradesh, India 2Department of Critical Care Medicine, Columbia Asia Hospital, Bengaluru, Karnataka, India Address for correspondence: Dr. Garima Kapoor, Department of Microbiology, Gandhi Medical College, Bhopal, Madhya Pradesh, India. E-mail: [email protected] Copyright : © 2017 Journal of Anaesthesiology Clinical Pharmacology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. Abstract Infections account for a major cause of death throughout the developing world. This is mainly due to the emergence of newer infectious agents and more specifically due to the appearance of antimicrobial resistance. With time, the bacteria have become smarter and along with it, massive imprudent usage of antibiotics in clinical practice has resulted in resistance of bacteria to antimicrobial agents. The antimicrobial resistance is recognized as a major problem in the treatment of microbial infections. The biochemical resistance mechanisms used by bacteria include the following: antibiotic inactivation, target modification, altered permeability, and “bypass” of metabolic pathway. Determination of bacterial resistance to antibiotics of all classes (phenotypes) and mutations that are responsible for bacterial resistance to antibiotics (genetic analysis) are helpful.
[Show full text]
Clinical Pharmacology—The Quarterback of Drug
Clinical Pharmacology— The Quarterback of Drug Development PEER REVIEWED Ellen Leinfuss; Julie Bullock [DOI: 10.14524/CR-17-0016] A quarterback’s job is to direct the team toward the end zone Clinical pharmacology accounts for about 50% and score as many points as possible. Considered the leader of of a drug label. Its scope ranges from facilitating the team, the quarterback is often responsible for calling the play; the discovery of new target molecules to deter- mining the effects of drugs in different popula- however, the quarterback isn’t just responsible for knowing how to tions. From both industry-wide and regulatory do his job—he has to know the responsibilities of every player on perspectives, the levers of clinical pharmacology the field to win the game. can address the huge challenges of late-stage attrition and increase the efficiency of drug development in the quest to bring the “ball” into the end zone. June 2017 20 Clinical Researcher Clinical pharmacology accounts for about 50% of a drug label FIGURE 1: Role of Clinical Pharmacology in the Drug Label Warning Warnings Contraindications and precautions Special dosage instructions Special populations Adverse Drug reactions interactions Clinical Dosage and pharmacology administration PK: ADME WHAT IS CLINICAL PHARMACOLOGY? in drug development due to scientific challenges in predicting efficacy and safety or characterizing Clinical pharmacology is the science of the sources of drug response variability at early, less relationship between drugs and humans. It focuses expensive stages of discovery. on drug action, and incorporates pharmacolog- Clinical pharmacology can help stakeholders ical principles and techniques into the clinical to address these challenges and improve decision development cycle.
[Show full text]
A Live Cell Nanobret Binding Assay Allows the Study of Ligand-Binding Kinetics to the Adenosine A3 Receptor
Purinergic Signalling https://doi.org/10.1007/s11302-019-09650-9 ORIGINAL ARTICLE A live cell NanoBRET binding assay allows the study of ligand-binding kinetics to the adenosine A3 receptor Monica Bouzo-Lorenzo1,2 & Leigh A. Stoddart 1,2 & Lizi Xia3 & Adriaan P. IJzerman3 & Laura H. Heitman 3 & Stephen J. Briddon1,2 & Stephen J. Hill1,2 Received: 25 November 2018 /Accepted: 14 February 2019 # The Author(s) 2019 Abstract There is a growing interest in understanding the binding kinetics of compounds that bind to G protein-coupled receptors prior to progressing a lead compound into clinical trials. The widely expressed adenosine A3 receptor (A3AR) has been implicated in a range of diseases including immune conditions, and compounds that aim to selectively target this receptor are currently under development for arthritis. Kinetic studies at the A3AR have been performed using a radiolabelled antagonist, but due to the kinetics of this probe, they have been carried out at 10 °C in membrane preparations. In this study, we have developed a live cell NanoBRET ligand binding assay using fluorescent A3AR antagonists to measure kinetic parameters of labelled and unlabelled compounds at the A3AR at physiological temperatures. The kinetic profiles of four fluorescent antagonists were determined in kinetic association assays, and it was found that XAC-ser-tyr-X-BY630 had the longest residence time (RT = 288 ± 62 min) at the A3AR. The association and dissociation rate constants of three antagonists PSB-11, compound 5, and LUF7565 were also determined using two fluorescent ligands (XAC-ser- tyr-X-BY630 or AV039, RT = 6.8 ± 0.8 min) as the labelled probe and compared to those obtained using a radiolabelled antagonist ([3H]PSB-11, RT = 44.6 ± 3.9 min).
[Show full text]
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
[Show full text]
Principles of Clinical Pharmacology Research
1 Principles of Clinical Pharmacology Research PHAR 5230 Principles of Clinical Pharmacology Research 2 Credits Fall Semester 2019 Location/Time: WDH 7-193/Life Sci 160; Mondays 10:10 – 12:05 pm Course Delivery Director: Mark Kirstein, Pharm.D. Associate Professor Experimental and Clinical Pharmacology 717 Delaware Room 459 Phone : 612-624-5689 E-mail : [email protected] Participating Faculty: Swayam Prabha, Ph.D., M.S., MBA L’Aurelle Johnson, Ph.D. Assistant Professor Assistant Professor Experimental and Clinical Pharmacology Experimental and Clinical Pharmacology Phone: 612-626-3545- 7-115C Weaver-Densford Hall Email: [email protected] Phone: 612-624-5430 Fax: 612-625-3927 Email: [email protected] Jeff Bishop, Pharm.D. Ling Li, Ph.D. Associate Professor Professor and VFW Endowed Chair Experimental and Clinical Pharmacology Experimental and Clinical Pharmacology 14-271 Moos T 4-208 MTRF Phone : 612-625-5435 Phone: 612-626-2359 Email : [email protected] Email: [email protected] Scott Chapman, Pharm.D. Debra Skaar, Pharm.D. Associate Professor Associate Professor Experimental and Clinical Pharmacology Experimental and Clinical Pharmacology 7-115E Weaver-Densford Hall 7-109 Weaver-Densford Hall [email protected] Phone: 612-626-3005 E-mail: [email protected] Ramaiah Muthyala, Ph.D., FRSC Mahmoud Al Kofahi, D.D.S., Ph.D. Research Associate Professor Assistant Professor Experimental & Clinical Pharmacology717 Experimental and Clinical Pharmacology Delaware Rm 519University of Minnesota 717 Delaware Room 464 Minneapolis, MN Phone : 612-624-1161 [email protected] Email : [email protected] Pamala Jacobson, Pharm.D. Wendy St Peter, Pharm.D. Professor Professor Experimental and Clinical Pharmacology Pharmaceutical Care and Health Systems 7-151 Weaver-Densford Hall 7-176 Weaver-Densford Hall Phone:612-624-6118 Phone: 612-625-5848 Email: [email protected] Email: [email protected] 2 Michael Walters, Ph.D.
[Show full text]
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification
0031-6997/03/5504-597–606$7.00 PHARMACOLOGICAL REVIEWS Vol. 55, No. 4 Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics 30404/1114803 Pharmacol Rev 55:597–606, 2003 Printed in U.S.A International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology RICHARD R. NEUBIG, MICHAEL SPEDDING, TERRY KENAKIN, AND ARTHUR CHRISTOPOULOS Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Institute de Recherches Internationales Servier, Neuilly sur Seine, France (M.S.); Systems Research, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina (T.K.); and Department of Pharmacology, University of Melbourne, Parkville, Australia (A.C.) Abstract ............................................................................... 597 I. Introduction............................................................................ 597 II. Working definition of a receptor .......................................................... 598 III. Use of drugs in definition of receptors or of signaling pathways ............................. 598 A. The expression of amount of drug: concentration and dose ............................... 598 1. Concentration..................................................................... 598 2. Dose. ............................................................................ 598 B. General terms used to describe drug action ...........................................
[Show full text]
Clinical Pharmacokinetics, 6Th Edition
JOHN E. MURPHY, PharmD, FASHP, FCCP Professor of Pharmacy Practice and Science and Associate Dean, College of Pharmacy Professor of Clinical, Family and Community Medicine College of Medicine The University of Arizona Tucson, Arizona Honorary Professor The University of Otago School of Pharmacy Dunedin, New Zealand Any correspondence regarding this publication should be sent to the publisher, American Society of Health-System Pharmacists, 4500 East-West Highway, Suite 900, Bethesda, MD 20814, attention: Special Publishing. The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product. Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation. The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. However, any user of this information is advised that the editors and ASHP are not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the document in any and all practice settings. Any reader of this document is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in this document and specifically disclaims any liability to any party for the accuracy and/or completeness of the material or for any damages arising out of the use or non-use of any of the information contained in this document.
[Show full text]